Ionis Total Liab vs Long Term Investments Analysis

IONS Stock  USD 33.94  1.46  4.12%   
Ionis Pharmaceuticals financial indicator trend analysis is infinitely more than just investigating Ionis Pharmaceuticals recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Ionis Pharmaceuticals is a good investment. Please check the relationship between Ionis Pharmaceuticals Total Liab and its Long Term Investments accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Ionis Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
For more information on how to buy Ionis Stock please use our How to Invest in Ionis Pharmaceuticals guide.

Total Liab vs Long Term Investments

Total Liab vs Long Term Investments Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Ionis Pharmaceuticals Total Liab account and Long Term Investments. At this time, the significance of the direction appears to have strong contrarian relationship.
The correlation between Ionis Pharmaceuticals' Total Liab and Long Term Investments is -0.68. Overlapping area represents the amount of variation of Total Liab that can explain the historical movement of Long Term Investments in the same time period over historical financial statements of Ionis Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Ionis Pharmaceuticals' Total Liab and Long Term Investments is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Liab of Ionis Pharmaceuticals are associated (or correlated) with its Long Term Investments. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Long Term Investments has no effect on the direction of Total Liab i.e., Ionis Pharmaceuticals' Total Liab and Long Term Investments go up and down completely randomly.

Correlation Coefficient

-0.68
Relationship DirectionNegative 
Relationship StrengthWeak

Total Liab

The total amount of all liabilities that a company has, including both short-term and long-term liabilities.

Long Term Investments

Long Term Investments is an item on the asset side of Ionis Pharmaceuticals balance sheet that represents investments Ionis Pharmaceuticals intends to hold for over a year. Ionis Pharmaceuticals long term investments may include different instruments such as stocks, bonds, real estate and cash.
Most indicators from Ionis Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Ionis Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Ionis Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
For more information on how to buy Ionis Stock please use our How to Invest in Ionis Pharmaceuticals guide.At this time, Ionis Pharmaceuticals' Selling General Administrative is comparatively stable compared to the past year. Tax Provision is likely to gain to about 33.9 M in 2024, whereas Sales General And Administrative To Revenue is likely to drop 0.16 in 2024.
 2021 2022 2023 2024 (projected)
Total Operating Expenses829M984M779.6M818.6M
Cost Of Revenue11M14M9.1M8.7M

Ionis Pharmaceuticals fundamental ratios Correlations

0.870.580.920.730.86-0.16-0.60.680.940.61.00.590.930.960.940.931.00.30.740.520.50.830.960.430.64
0.870.720.930.340.960.21-0.80.410.690.170.870.490.980.920.840.980.890.230.740.510.590.970.840.40.32
0.580.720.650.110.640.36-0.530.110.540.20.570.220.690.550.510.690.58-0.460.410.420.350.70.560.230.22
0.920.930.650.430.930.18-0.80.40.790.330.910.50.970.930.90.980.930.340.720.670.610.910.910.430.33
0.730.340.110.430.38-0.75-0.040.90.830.870.730.590.430.610.660.430.70.240.50.180.090.260.670.320.86
0.860.960.640.930.380.17-0.840.430.720.180.860.570.940.910.890.940.880.320.810.50.490.940.850.520.25
-0.160.210.360.18-0.750.17-0.38-0.8-0.31-0.62-0.17-0.40.17-0.05-0.160.17-0.14-0.09-0.110.090.30.33-0.1-0.13-0.64
-0.6-0.8-0.53-0.8-0.04-0.84-0.38-0.12-0.420.12-0.6-0.62-0.78-0.64-0.76-0.78-0.62-0.27-0.8-0.7-0.47-0.81-0.54-0.710.07
0.680.410.110.40.90.43-0.8-0.120.720.690.690.660.440.610.660.430.670.230.530.230.090.280.610.350.79
0.940.690.540.790.830.72-0.31-0.420.720.810.930.570.780.830.870.780.920.160.660.480.310.640.910.420.72
0.60.170.20.330.870.18-0.620.120.690.810.590.360.30.410.480.30.56-0.030.260.250.020.10.570.160.83
1.00.870.570.910.730.86-0.17-0.60.690.930.590.60.930.960.940.931.00.30.740.520.490.830.950.430.65
0.590.490.220.50.590.57-0.4-0.620.660.570.360.60.490.510.770.490.590.20.880.530.130.420.460.860.38
0.930.980.690.970.430.940.17-0.780.440.780.30.930.490.950.881.00.940.280.730.560.610.960.890.390.4
0.960.920.550.930.610.91-0.05-0.640.610.830.410.960.510.950.90.950.970.40.720.440.570.890.950.340.53
0.940.840.510.90.660.89-0.16-0.760.660.870.480.940.770.880.90.890.940.350.880.640.450.80.870.690.51
0.930.980.690.980.430.940.17-0.780.430.780.30.930.491.00.950.890.940.290.730.580.610.960.90.40.39
1.00.890.580.930.70.88-0.14-0.620.670.920.561.00.590.940.970.940.940.320.750.520.530.850.950.420.62
0.30.23-0.460.340.240.32-0.09-0.270.230.16-0.030.30.20.280.40.350.290.320.290.10.330.240.330.11-0.01
0.740.740.410.720.50.81-0.11-0.80.530.660.260.740.880.730.720.880.730.750.290.520.290.720.640.810.34
0.520.510.420.670.180.50.09-0.70.230.480.250.520.530.560.440.640.580.520.10.520.330.430.470.560.1
0.50.590.350.610.090.490.3-0.470.090.310.020.490.130.610.570.450.610.530.330.290.330.570.480.040.1
0.830.970.70.910.260.940.33-0.810.280.640.10.830.420.960.890.80.960.850.240.720.430.570.810.390.28
0.960.840.560.910.670.85-0.1-0.540.610.910.570.950.460.890.950.870.90.950.330.640.470.480.810.290.57
0.430.40.230.430.320.52-0.13-0.710.350.420.160.430.860.390.340.690.40.420.110.810.560.040.390.290.15
0.640.320.220.330.860.25-0.640.070.790.720.830.650.380.40.530.510.390.62-0.010.340.10.10.280.570.15
Click cells to compare fundamentals

Ionis Pharmaceuticals Account Relationship Matchups

Ionis Pharmaceuticals fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets3.2B2.4B2.6B2.5B3.0B3.1B
Short Long Term Debt Total772.0M808.9M1.2B1.3B1.5B1.5B
Other Current Liab136.9M(128.4M)127.6M189.3M215.6M226.4M
Total Current Liabilities273M290M241M312M448.1M470.5M
Total Stockholder Equity1.5B843M772M573M386.7M265.7M
Property Plant And Equipment Net154M181M178M256M242.9M255.1M
Net Debt(1.8B)(1.1B)(954M)(642M)1.1B1.1B
Retained Earnings(707.5M)(1.2B)(1.2B)(1.4B)(1.8B)(1.7B)
Cash2.5B1.9B2.1B2.0B399.3M534.5M
Non Current Assets Total512M260M267M331M348.2M365.6M
Non Currrent Assets Other358M51.1M60.0M34.6M62.3M34.5M
Cash And Short Term Investments2.5B1.9B2.1B2.0B2.3B2.4B
Common Stock Shares Outstanding142.9M139.6M141.0M141.8M143.2M83.9M
Liabilities And Stockholders Equity3.2B2.4B2.6B2.5B3.0B3.1B
Non Current Liabilities Total1.3B1.3B1.6B1.6B2.2B2.3B
Other Current Assets158M162M168M157.7M184.4M193.7M
Other Stockholder Equity2.2B2.1B2.0B2.1B2.2B2.3B
Total Liab1.5B1.5B1.8B2.0B2.6B2.7B
Total Current Assets2.7B2.1B2.3B2.2B2.6B2.8B
Short Term Debt2.0M293.2M3.5M7.5M53.2M55.8M
Intangible Assets24.0M25.7M27.9M29.0M33.4M24.2M
Accounts Payable16.1M17.2M11.9M17.9M26.0M27.3M
Net Receivables63M76M62M25.5M97.8M102.7M
Property Plant And Equipment Gross153.7M181.1M280.7M256M339.7M356.7M
Accumulated Other Comprehensive Income(25.3M)(21.1M)(32.7M)(57.5M)(32.6M)(31.0M)
Short Term Investments1.8B1.5B1.2B1.7B1.9B2.0B
Other Assets310.6M78.0M319M35.0M40.2M57.3M
Long Term Debt770.0M515.7M1.2B1.2B1.2B1.3B
Property Plant Equipment153.7M181.1M178.1M74.3M85.4M79.6M
Other Liab490.1M424M352M287.8M330.9M170.0M
Current Deferred Revenue118M108M98M91M151.1M158.7M
Inventory18.2M22.0M24.8M22.0M28.4M29.8M
Net Tangible Assets1.4B815.4M742.7M572.9M658.8M531.9M
Retained Earnings Total Equity(707.5M)(1.2B)(1.2B)(1.4B)(1.3B)(1.4B)
Long Term Debt Total770.0M515.7M1.2B1.2B1.4B1.4B
Capital Surpluse2.2B2.1B2.0B2.1B2.4B1.7B

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Ionis Stock Analysis

When running Ionis Pharmaceuticals' price analysis, check to measure Ionis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ionis Pharmaceuticals is operating at the current time. Most of Ionis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Ionis Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ionis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Ionis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.